Technology | April 16, 2013

Maquet Air-Band Radial Compression Device Receives FDA 510(k) Clearance, CE Mark

Device to assist hemostasis of the radial artery after a transradial procedure

April 16, 2013 — Maquet Cardiovascular LLC has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and European CE mark approval for its new Air-Band Radial Compression Device. Indicated to assist hemostasis of the radial artery after a transradial procedure, the device is designed to compress the radial artery puncture site while maintaining site visibility and a secure fit around the wrist. Air-Band will be commercially available in the European Union later this month and in the United States in April.

"We have found that Air-Band is easy to use, reliable and effective in achieving hemostasis following radially accessed coronary catheterization procedures," said Christian Valina, M.D., interventional cardiologist at the University Heart Centre of Bad Krozingen in Germany. "My colleagues and I were impressed by the secure fit around the wrist that the adhesive band provides. We believe that Air-Band represents important progress towards ensuring patient safety and comfort during these important procedures."

"Drawing on our significant experience in hemostasis management, we designed Air-Band to provide all the valued benefits of our Safeguard Pressure Assisted Device — which assists in obtaining and maintaining hemostasis after a femoral procedure — and applied our knowledge to a radial application," said Christian Keller, president and CEO of Maquet Cardiovascular. "Both devices simplify hemostasis management by delivering hands-free adjustable pressure, offering simple application and removal, and providing clear site visibility and assessment without compromising patient comfort, which is a priority for us."

Air-Band is a 26-cm long, latex-free, self-adhesive wristband with a clear window and bulb that facilitate visualization of the puncture site. A luer valve on the end of the clear fill tube enables any standard syringe to be connected to inflate and deflate the bulb with air to provide compression of the radial puncture site.

With its textile wristband, Air-Band contributes to patient comfort, as it neither cuts into the skin nor has protruding plastic parts. The adhesive enables a secure fit around all patient wrists, avoiding movement and dislocation. Both the size and shape of Air-Band’s inflatable bulb minimize the compression risk to surrounding nerve structures or areas other than the radial puncture site. The standard luer valve allows easy inflation and deflation with any standard luer syringe.

For more information: www.maquet.com

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init